Back Dictionary Export CSV
Filter: Clear
ENCORE_PATIENT_ID MERGED_REGIMEN_ID HEIGHT_AT_START_OF_REGIMEN WEIGHT_AT_START_OF_REGIMEN INTENT_OF_TREATMENT DATE_DECISION_TO_TREAT START_DATE_OF_REGIMEN MAPPED_REGIMEN CLINICAL_TRIAL CHEMO_RADIATION BENCHMARK_GROUP LINK_NUMBER
240002424 240010271 0 78.2 Curative (C) 2021-12-15 2021-12-16 DA 02 null CISPLATIN + CYTARABINE + ETOPOSIDE 100682624
240002427 240010273 1.9 82.8 Curative (C) 2019-09-25 2019-10-02 DA 02 null ETOPOSIDE 100828896
240002428 240010274 1.64 97 null 2016-11-20 2016-11-21 null 02 null MELPHALAN 101526696
240002430 240010275 0 28.1 Curative (C) 2020-06-12 2020-07-06 ALL Interim Guide 2019 Consolidation A 01 null PEMBROLIZUMAB 100702960
240002437 240010277 1.9 74.7 03 2022-02-09 2022-02-09 CLADRIBINE 2 N CYTARABINE HIGH DOSE 101505664
240002444 240010278 1.83 63.1 null 2019-05-02 2019-05-05 GEMTUZUMAB OZOGAMICIN 02 null ALL UKALL2011 AUG BFM CONS C 100239144
240002447 240010279 1.77 78 null 2017-04-02 2017-08-05 DA 3 + 10 01 null CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB 100679385
240002448 240010280 1.62 51.6 null null 2020-06-07 null null null IBRUTINIB 100616707
240002454 240010282 0 17.1 null null 2016-12-02 IPILIMUMAB + NIVOLUMAB null null BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB 100455766
240002458 240010283 1.62 78 Curative (C) 2022-01-09 2022-01-13 CYCLO + RITUXIMAB + VINCRISTINE N null CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE 101461048
240002475 240010285 1.12 43 03 2019-01-14 2019-01-23 Trial Unspecified 02 null AZACITIDINE + VENETOCLAX 101163175
240002478 240010286 1.56 71.1 null 2018-10-31 2018-11-09 R CODOX M null N ALL UKALL2011 CAP INT MAINT C 100059700
240002486 240010287 1.68 76 Curative (C) 2019-01-23 2019-01-23 IVAC 02 null ETOPOSIDE PBSCT MOBILISAT (1.6G/M2) 101706950
240002494 240010290 1.6 133 03 null 2020-04-16 GEMCITABINE + OXALIPLATIN + RITUXIMAB N N CYTARABINE + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB 101692205
240002529 240010293 1.56 84 null 2020-09-02 2020-09-02 ALL UKALL2011 Aug BFM Cons C PegAsp null null VENETOCLAX 101794967
240002530 240010294 1.67 70 Curative (C) 2016-03-24 2016-04-28 Cytarabine High Dose 02 null CYCLOPHOSPHAMIDE 101456655
240002533 240010296 1.5 91.2 null 2018-04-24 2018-05-09 CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB 02 N AML DOWNS AIE 100183101
240002539 240010297 1.91 52.2 Adjuvant (A) 2018-12-12 2018-12-14 CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin 02 N TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN 100615225
240002542 240010298 1.84 73.7 Curative (C) 2021-10-30 2021-11-04 null 02 null DABRAFENIB 101652203
240002543 240010299 null null Curative (C) 2021-11-29 2021-11-29 ALL UKALL2011 Maintenance A2 N null TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN 100371794
240002552 240010302 1.67 57.2 null 2020-12-30 2021-03-11 null Y N ALL ALLR3: S/IR CONS 100131616
240002553 240010303 1.66 90 null 2017-05-04 2017-05-26 CYCLOPHOSPHAMIDE + FLUDARABINE 01 null METHOTREXATE INTRATHECAL 100040788
240002563 240010304 1.76 80.4 null 2019-05-06 2019-05-06 AML MyeChild 01 HD AraC 02 null APML ATRA 100236291
240002565 240010305 1.71 80.4 Curative (C) 2018-12-09 2018-12-09 R GCVP null N BUSULFAN 100932525
240002577 240010308 1.75 106.6 Disease modification (D) 2020-12-05 2020-12-07 null 02 null AML MYECHILD 101309020
240002578 240010309 1.67 51.3 03 2019-10-11 2019-10-12 CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin 02 null CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE 101858176
240002580 240010310 1.78 74 null null 2021-01-08 Cladribine (subcut) 5 days null null CYCLOPHOSPHAMIDE 100624205
240002583 240010311 1.6 82.3 null null 2021-08-16 Cytarabine High Dose 02 N ALL UKALL2011 IND B 100560456
240002596 240010312 1.67 107.9 Curative (C) null 2017-07-28 null null N ALL ALLR3: S/IR CONS 100426877
240002597 240010313 1.62 53.9 Curative (C) null 2018-10-12 ALL UKALL2011 Aug BFM Cons C PegAsp null N DASATINIB 101029319
240002604 240010314 1.69 85.5 Curative (C) 2016-11-11 2018-01-10 AML Int Guide HD Cytarabine (3 + 4) 02 null CYTARABINE + ETOPOSIDE + IFOSFAMIDE 100898534
240002610 240010315 1.74 57.9 Curative (C) 2019-11-05 2019-12-31 TRANSPLANT BEAM 01 N POMALIDOMIDE 100238819
240002612 240010316 1.76 10.4 Curative (C) 2021-03-02 2021-03-08 null 02 null CARBOPLATIN + VINCRISTINE 100396553
240002613 240010317 1.59 26.5 03 2016-07-05 2016-07-05 null 02 N RUXOLITINIB 101654756
240002619 240010319 1.83 102.6 03 2019-08-12 2019-08-18 null 02 null ALL UKALL2011 DEL INT A 101456528
240002620 240010320 1.7 28.4 Disease modification (D) 2020-04-19 2020-05-15 Cytarabine High Dose 01 null IMATINIB 100852396
240002631 240010322 1.9 79.7 null 2019-03-22 2019-05-30 null 2 null RUXOLITINIB 100610839
240002632 240010323 1.77 31.9 null 2016-05-25 2016-06-10 FLAG + Idarubicin 02 null NOT MATCHED 100420743
240002637 240010324 null 117 null 2018-02-23 2018-02-23 CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB 02 null ALL UKALL2011 MAINTENANCE 100056675
240002651 240010326 1.54 0 Curative (C) 2017-11-30 2017-12-10 null 02 null TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN 100487371
240002657 240010327 1.76 65 03 2020-01-31 2020-02-12 Trial Unspecified 02 null GEMTUZUMAB OZOGAMICIN 100373006
240002661 240010329 null 9.5 Curative (C) 2020-01-06 2020-01-07 null 02 N MIDOSTAURIN 100392129
240002681 240010331 0 88 Curative (C) null 2017-03-22 Bortezomib + Cyclophos + Dex null null NOT MATCHED 101392613
240002691 240010332 1.76 58.1 null 2018-06-01 2018-06-28 IBRUTINIB 02 null BUSULFAN 101090800
240002697 240010333 1.66 77 null 2019-03-09 2019-04-02 CYCLO + RITUXIMAB + VINCRISTINE null null RUXOLITINIB 100451551
240002702 240010334 0 85 null 2019-11-08 2020-01-01 CHOP - 21 days 02 null TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN 101607922
240002704 240010335 1.7 112.9 Curative (C) null 2021-04-04 IMATINIB null N ANAGRELIDE 101247286
240002710 240010337 1.5 121.1 Not known (9) 2021-08-04 2021-08-04 IBRUTINIB 02 null AML MYECHILD 01 A MITOZANTRONE/CYTARABINE 100363568
240002733 240010344 1.8 73.7 03 2021-05-10 2021-05-10 null 01 N PEG INTERFERON 101528355
240002737 240010345 1.7 77 null 2019-04-04 2019-04-11 R CODOX M 02 null NILOTINIB 100926406